



Justin Gover, Chief Executive Officer

Justin Gover is the founding Chief Executive Officer of GW Pharmaceuticals plc, the parent company of Greenwich Biosciences. He has served in this role since January 1999. Throughout this 19-year period, Mr. Gover has served on GW's Board of Directors.

As Chief Executive Officer, Mr. Gover has been the lead executive responsible for the running of the company's operations, leading equity financings as well as corporate strategy and business development activities. He raised initial rounds of private capital, following which he led the company's initial public offering on the AIM stock exchange in London in 2001. From 2003-2007, Mr. Gover concluded licensing agreements with Otsuka, Novartis, Bayer, Ipsen and Almirall, yielding payments in excess of \$100m plus future milestones and royalties.

In 2013, Mr. Gover led GW's initial public offering on Nasdaq. The company's market capitalization at the time of this Nasdaq IPO was \$150m and has since increased to \$3.5bn. Since 2013,

Mr. Gover has led an additional four follow-on offerings and raised over \$1bn.

In 2015, Mr. Gover relocated from the U.K. to the U.S. to open GW Pharmaceuticals' U.S. subsidiary, Greenwich Biosciences, in California, where he is overseeing the build-out of the U.S. commercial operations.

Prior to joining GW, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a U.K.-based Nasdaq listed company that utilized drug delivery technologies to develop improved formulations. At Ethical, he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations.

Mr. Gover holds an MBA from the INSEAD business school in France and a B.Sc. (Hons) from Bristol University. He is a member of the Young President's Organization.